ABSCI CORP (ABSI)
US00091E1091 - Common Stock
Tuesday Sector Leaders: Diagnostics, Biotechnology Stocks
Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024
Absci to Participate in the 23rd Annual Needham Virtual Healthcare Conference
ABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Absci (NASDAQ:ABSI) just reported results for the fourth quarter of 2023.Absci ...
ABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q4 2023
ABSI stock results show that Absci missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
Initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody Entered into collaboration with AstraZeneca for up to $247M in...
Latest Updates of Viva Biotech's Portfolio Companies
/PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term...
Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
VANCOUVER, Wash., March 01, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today...
Investors Snag ABSI Even Cheaper Than Its Secondary Stock Offering
Absci prices $75M equity offering at $4.50 per share (NASDAQ:ABSI)
Absc (ABSI) priced an underwritten public offering of 16.7M shares at $4.50 per share. Underwriters have a 30-day option to purchase additional shares.
Absci Announces Pricing of Public Offering of Common Stock
Absci Announces Pricing of Public Offering of Common Stock
VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today...
Absci commences underwritten offering of shares (NASDAQ:ABSI)
Absci Corporation (ABSI) has commenced a public offering of $75M of common stock, with an option for underwriters to purchase an additional $11.25M.
Absci Announces Proposed Public Offering of Common Stock
Absci Announces Proposed Public Offering of Common Stock
VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company,...
Absci begins IND-enabling studies for ABS-101 antibody designed using gen AI (NASDAQ:ABSI)
Absci Corporation has initiated IND-enabling studies for ABS-101, an anti-TL1A antibody developed using their generative AI foundation model.
Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI
IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after
Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI
IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after...
Absci to Participate in Upcoming Investor Conferences
Absci Appoints Professor Sir Mene Pangalos to its Board of Directors
Absci to Participate in the 26th Annual Needham Growth Conference
Absci to Participate in the 26th Annual Needham Growth Conference
VANCOUVER, Wash. and NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced...